This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven second-quarter sales. Results will provide clarity on the impact of coronavirus on the company's business.
Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data
by Kinjel Shah
Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.
The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline
Glaxo, CureVac to Develop mRNA Vaccines for Infectious Disease
by Zacks Equity Research
Glaxo (GSK) signs a pact with CureVac for the development/commercialization of mRNA-based vaccines and monoclonal antibodies aimed at infectious disease pathogens.
Top Stock Reports for Bank of America, Abbott & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Abbott Laboratories (ABT) and Chevron (CVX).
Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.
Pharma Stock Roundup: J&J Q2 Earnings, FDA Approvals, Fast Track Tags & More
by Kinjel Shah
J&J (JNJ) beats Q2 estimates for earnings and sales. FDA grants fast track designation to Pfizer's (PFE) coronavirus vaccine candidates.
The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, BioNTech, Pfizer, GlaxoSmithKline and Sanofi
Glaxo's Multiple Myeloma Candidate Gets FDA Committee Nod
by Zacks Equity Research
Glaxo's (GSK) belantamab mafodotin gets FDA's Oncologic Drugs Advisory Committee votes as its benefits outweigh risks for relapsed/refractory multiple myeloma patients.
Markets Bet Big on Coronavirus Vaccine Stocks: 3 Front Runners
by Tirthankar Chakraborty
As investors cheer signs of progress in COVID-19 vaccine development, here're three stocks that are worth keeping an eye on.
Merck's Keytruda Gets Priority Review for Lymphoma Indication
by Zacks Equity Research
FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.
Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal
by Kinjel Shah
Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs
Merck's Keytruda Combo Gets CRL for First-Line Liver Cancer
by Zacks Equity Research
FDA issues complete response letter to Merck (MRK) and Eisai's applications seeking approval of Keytruda+Lenvima for first-line HCC.
AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck's Lynparza gets approval in the EU for treating patients with germline BRCA-mutated metastatic pancreatic cancer.
Glaxo Signs Another Deal to Develop a Coronavirus Vaccine
by Zacks Equity Research
Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.
4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine
by Ritujay Ghosh
The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.
Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study
by Zacks Equity Research
Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.
Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus
by Kinjel Shah
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
Merck Gets FDA Nod for Keytruda Use in Colorectal Cancer
by Zacks Equity Research
FDA approves Merck's (MRK) Keytruda for first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer.
J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus
by Zacks Equity Research
Johnson & Johnson (JNJ) discontinues phase III study of Stelara (ustekinumab) in systemic lupus erythematosus.
GlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $40.55 in the latest trading session, marking a -1.39% move from the prior day.
Merck's Keytruda Wins FDA Nod for Squamous Cell Skin Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda for recurrent or metastatic cutaneous squamous cell carcinoma, a form of skin cancer, gets approval from the FDA.
3 Best GARP Stocks to Beat Pandemic-Led Market Inefficiency
by Urmimala Biswas
The unprecedented global health crisis is providing a psychological shock to the investment world.
Sanofi Expands Agreement With Translate Bio for mRNA Vaccines
by Zacks Equity Research
Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. The companies are already developing a mRNA vaccine candidate to combat COVID-19.
Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies
by Zacks Equity Research
Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.